Invited article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas

Neurology

Volumn 71, Issue 5, 2008, Pages 365-373

  Mason, Warren P ^a,c   Cairncross, J Gregory ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH INHIBITOR; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE; TUMOR MARKER;

ANIMAL; BRAIN TUMOR; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; GENETICS; GLIOMA; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR BIOLOGY; RADIOTHERAPY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GLIOMA; GROWTH INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR BIOLOGY; RADIOTHERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 67649259009     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000319721.98502.1b     Document Type: Article

References (88)

1. DeAngelis L. Brain tumors. N Engl J Med 2001;344:114- 123.
2. Burger P, Scheithauer B. Tumors of the Central Nervous System. Washington, DC: Armed Forces Institute of Pathology, 1994.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [see comment]. N Engl J Med 2005;352:987- 996.
4. Kleihues P, Cavanee W. World Health Organization Classification of Tumors: Tumors of the Nervous System: Pathology and Genetics. Lyon: IRAC Press, 2000.
5. van den Bent M, Carpentier AF, Brandes A, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas: a randomized European Organisation for Research and Treatment of cancer phase III trial. J Clin Oncol 2006;24:2715-2722.
6. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendrogli-oma: intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006;24:2707-2714.
7. Fortin D, Cairncross GJ, Hammond RR. Oligodendrogli-oma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 1999;45:1279-1291.
8. Olson J, Riedel E, DeAngelis L. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000;54:1442-1448.
9. Karim A, Afra D, Cornu P, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BR04: an interim analysis. Int J Radiat Oncol Biol Phys 2002;52:316-324.
10. Burger PC. What is an oligodendroglioma? Brain Pathol 2002;12:257-259.
11. Walker C, du Plessis DG, Joyce KA, et al. Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin Cancer Res 2003;9:4841- 4851.
12. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology 2005;25:1-7.
13. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445- 1453.
14. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64:6892-6899.
15. Newton H. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors: part 3: brain tumor invasiveness. Exp Rev Anticancer Ther 2004; 4:803-821.
16. Newton H. Molecular neuro-oncology and development of targeted therapeutic strategies fro brain tumors: part 1: growth factor and Ras signaling pathways. Exp Rev Anti-cancer Ther 2005;3:595-614.
17. Newton H. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors: part 2: PI3K/Akt/PTEN. mTOR, SHH/PTCH and angiogenesis Exp Rev Anticancer Ther 2005;4:105-128.
18. Newton H. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors: part 4:53 signaling pathway. Exp Rev Anticancer Ther 2005;5: 177-191.
19. Newton H. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors: p art 5: apoptosis and cell cycle. Exp Rev Anticancer Ther 2005;5: 355-378.
20. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12:2013-2021.
21. Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oli-goastrocytoma recurrent after radiotherapy: a Phase II study. Cancer 2004;101:2079-2085.
22. van den Bent M, Taphoorn M, Brandes A, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003;21:2525-2528.
23. van den Bent M, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligoden-droglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 2003;14:599-602.
24. van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 1998;51:1140-1145.
25. van den Bent M. Adjuvant treatment of high grade glio-mas. Ann Oncol 2006;17(suppl 10):186-190.
26. Siker ML, Chakravarti A, Mehta MP. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Crit Rev Oncol Hematol 2006;60:99-111.
27. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial [see comment] [erratum appears in 2006;367:1818]. Lancet 2005;366:985-990.
28. Karim A, Matt B, Hatlevoli R, et al. A randomized trial of dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996;36:549-556.
29. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Group/Radiation therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267-2276.
30. Mason WP. Progress in clinical neurosciences: advances in the management of low-grade gliomas. Can J Neurol Sci 2005;32:18-26.
31. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendro-gliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138.
32. Kaloshi G, Benouaich-Ameil A, Diakite F, et al. Temozolomide for low-grade gliomas. Predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68:1831-1836.
33. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas [see comment]. Ann Oncol 2003;14:1715-1721.
34. Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 2003;15:197-203.
35. Watanabe K, Tachibana O, Sato K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblas-tomas. Brain Pathol 1996;6:217-223.
36. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 2002;62:3335-3339.
37. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11: 1462-1466.
38. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-489.
39. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with ana-plastic astrocytoma and glioblastoma multiforme J Natl Cancer Inst 2001;93:1246-1256.
40. Zhou XP, Li YJ, Hoang-Xuan K, et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological analysis. Int J Cancer 1999;84:150-154.
41. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
42. Reifenberger J, Reifenberger G, Liu L, James CD, Wech-sler JW, Collins VP. Molecular genetic analysis of oligo-dendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-1190.
43. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988-994.
44. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10; p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendrogli-oma. Cancer Res 2006;66:9852-9861.
45. Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001;57:1278-1281.
46. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 2001;60:1181-1189.
47. Wolter M, Reifenberger J, Blaschke B, et al. Oligodendro-glial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 2001;60:1170-1180.
48. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000;59:495-503.
49. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor expression in oligodendroglial tumors. Am J Pathol 1996;149:29-35.
50. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003;62:111-126.
51. Esteller M, Hamilton S, Burger P, Baylin S, Herman J. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promotor hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
52. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-1874.
53. Friedman H, McLendon R, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-3857.
54. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactiva-tion of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354.
55. Jaeckle K, Eyre H, Townsend J, et al. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310-3315.
56. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma [see comment]. N Engl J Med 2005;352:997-1003.
57. Hegi M, Stupp R. Correlative studies in neuro-oncology trials: should they influence treatment? Curr Oncol Rep 2006;8:54-57.
58. Walker C, Haylock B, Husband D, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 2006;66:1661-1667.
59. Walker C, Haylock B, Husband D, et al. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms. Br J Cancer 2006;95:1424-1431.
60. Kujas M, Lejeune J, Benouaich-Ameil A, et al. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas. Ann Neurol 2005;58:322-326.
61. Ino Y, Betensky R, Zlatescu M, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-845.
62. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T. Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neuro-Oncol 2006;79:153-157.
63. Buckner JC, Gesme D, Jr, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocy-toma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-255.
64. Everhard S, Kaloshi G, Benouaich-Ameil A, et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006;60:740-743.
65. Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oli-godendroglioma: a prospective GICNO study. J Clin Oncol 2006;24:4746-4753.
66. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas. Response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006; 106:1759-1765.
67. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifen-berger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-385.
68. Ueki K. Oligodendroglioma: impact of molecular biology on its definition, diagnosis and management. Neuropathology 2005;25:247-253.
69. Nutt CL. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. Neurosurg Focus 2005;19:E2.
70. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-1607.
71. Hoang-Xuan K, Idbaih A, Mokhtari K, Sanson M. Vers une classification moleculaire des gliomes. Bull Cancer 2005;92:310-316.
72. van den Bent MJ. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. Semin Oncol 2003;30:39-44.
73. Jaeckle K, Ballman K, Rao R, Jenkins R, Buckner J. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 2006;24:1246-1252.
74. Watanabe T, Katayama Y, Komine C, et al. O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2005;113:581-587.
75. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-6970.
76. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122-1128.
77. Aldape KD, Ballman K, Furth A, et al. Immunohisto-chemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004;63:700-707.
78. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors [see comment] [erratum appears in 2006; 354:884]. N Engl J Med 2005;353:2012-2024.
79. Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2007;13:378-381.
80. Holland E. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001;2:120-129.
81. Penas-Prado M, Gilbert MR. Molecularly targeted therapies for malignant glioma: advances and challenges. Exp Rev Anticancer Ther 2007;7:641-661.
82. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 2006;11:152-164.
83. Simpson L, Galanis E. Recurrent glioblastoma multi-forme: advances in treatment and promising drug candidates. Exp Rev Anticancer Ther 2006;6:1593-1607.
84. Sathornsumetee S, Rich JN. New treatment strategies for malignant glioma. Exp Rev Anticancer Ther 2006;6: 1087-1104.
85. Batchelor T, Sorensen AG, Ancukiewicz M, et al. A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Proc Am Soc Clin Oncol 2007;25:75s. Abstract #2001.
86. Goli KJ, Desjardins A, Herndon JE, et al. Phase II trial of bevaci-zumab and irinotecan in the treatment of malignant gliomas. Proc Am Soc Clin Oncol 2007;25:75s. Abstract #2003.
87. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2006;13:1253-1259.
88. van den Bent MJ, Stupp R, Brandes AA, Lacombe D. Current and future trials of the EORTC brain tumor group. Onkologie 2004;27:246-250.